Welcome to our dedicated page for Xcelerate news (Ticker: XCRT), a resource for investors and traders seeking the latest updates and insights on Xcelerate stock.
Xcelerate, Inc. (XCRT) publishes frequent updates on its progress in medical technology, AI-assisted virtual health and consumer health and beauty products. The news flow provides insight into how the company is executing its business plan, adjusting its portfolio of assets and advancing its intellectual property.
Recent press releases describe Xcelerate’s decision to sell its majority interest in the ESN Group of companies in an all-cash transaction to Noble Labs Holdings, LLC, with the stated goal of refocusing on its original mission of implementing AI-aided medical technology and virtual health care in Africa through its majority-owned subsidiary, AfiyaSasa Africa, LLC. Other announcements highlight renewed emphasis on the AfiyaSasa project, including plans to launch an AI-assisted patient portal in Tanzania and to acquire a clinical care setting in which the technology can be trialed, tested and applied.
News items also cover developments in Xcelerate’s medical device patents, such as the commencement of the nationalization process for PCT international patent applications related to a Surgical Tool with Targeting Guidance that introduces a "first-person view" to the surgical theatre. Additional releases discuss corporate matters, including changes of auditors, re-audits of financial statements, filings of annual and semi-annual reports, amendments to registration statements, and the engagement of an investment bank to assist with capital raising and potential up-listing to a national exchange.
Investors and observers can use the XCRT news feed on this page to follow company statements on AI-driven healthcare initiatives, patent filings, divestitures, funding arrangements and shareholder communications, all in one place.
Xcelerate, Inc. (OTC Pink: XCRT) has announced the acquisition of a significant patent portfolio from HS Pharmaceuticals, aimed at advancing innovative medical technologies. CEO Michael O’Shea and HS Pharmaceuticals CEO Jon Wilken discussed this strategic move in a recent interview, emphasizing the potential for collaboration in developing groundbreaking treatments, particularly in chronic wound care and oncology. This acquisition follows over two years of negotiations and aligns with Xcelerate's mission to incorporate cutting-edge innovations into the medical field, addressing critical health challenges.
Xcelerate, Inc. (OTC PINK:XCRT) has announced the acquisition of a portfolio of patents and technology licenses from HS Pharmaceuticals LLC, focusing on oncology and healthcare products. Mr. Jon Wilken, former President and CEO of BILO Inc., is joining Xcelerate's Board of Directors. Wilken brings 30 years of experience in retail and will assist in integrating the acquired patents into Xcelerate's business strategy. The company has also acquired a 51% stake in AfiyaSasa Africa, LLC, a medical technology firm leveraging AI and AR.
Xcelerate, Inc. (OTC PINK:XCRT) announced the acquisition of a patent portfolio from HS Pharmaceuticals LLC, enhancing its focus on dermatological products for chronic wounds and infections. The deal includes four issued and one pending U.S. patents, as well as two issued and one pending European patent, totaling millions in developmental costs. The acquisition involves issuing 10 million shares of restricted common stock and establishing a profit-sharing arrangement. This move aims to strengthen Xcelerate's technology base and aligns with its strategy to acquire cutting-edge medical innovations.
Xcelerate, Inc. (OTC Markets: XCRT) announced the engagement of SmallCapVoice.com, an investor relations firm, to enhance communication with shareholders. CEO Michael O'Shea highlighted the importance of this partnership in increasing corporate exposure and sharing developments at Xcelerate. The recent pilot program launch in Africa via its subsidiary, AfiyaSasa Africa, was noted as a significant milestone. SmallCapVoice.com aims to support Xcelerate's mission as a socially responsible global entity.
Xcelerate, Inc. (OTC Pink: XCRT) has initiated a pilot program in partnership with AfiyaSasa Africa, LLC to enhance healthcare delivery in Tanzania using AI and augmented reality. The company's 51% stake in ASA aims to address the shortage of medical professionals identified by Dr. Dilan Ellegala, who highlighted there were merely two neurosurgeons for 44 million people in the region. This innovative approach seeks to leverage advanced technology to improve medical services. More details can be found in the interview conducted by SmallCapVoice.com.
Xcelerate, Inc. (OTC Markets:XCRT) has signed a Membership Interest Purchase Agreement to acquire a 51% interest in AfiyaSasa Africa, LLC, a medical technology and virtual health start-up founded by Dr. Dilan Ellegala and Doyle Word. Additionally, Xcelerate has obtained patent pending status for its invention, 'Surgical Tools with Targeting Guidance', aimed at enhancing surgical procedures through improved tool handling and precision. This represents the beginning of a series of planned patents as Xcelerate advances its mission of integrating engineering with clinical care.
Xcelerate, Inc. (OTCMarkets: XCRT) announced the appointment of Thomas E. Mannle, Jr. to its Advisory Board, effective immediately. Thomas, a retired Lieutenant Colonel from the U.S. Army Reserve, brings over 25 years of consulting experience in healthcare and defense. His expertise includes planning, budgeting, and technology integration in organizations. Xcelerate's CEO, Michael O'Shea, stated that Thomas would provide invaluable guidance on advancing their project alliance with AfiyaSasa Africa and the development of patentable med-tech. The company expressed gratitude to its partners and investors for their support.
Xcelerate, Inc. (OTC PINK:XCRT) has acquired majority control of AfiyaSasa Africa, LLC, which focuses on medical technology for developing countries. A pilot program will launch in Tanzania across four hospitals, potentially expanding to a fifth location. The program aims to establish operational beta sites by Q2 2022 and generate revenue by the end of 2022. CEO Michael O'Shea highlighted the team's rapid progress and plans to up-list to the QB market to attract more investors.
On March 10, 2022, Xcelerate (OTC Pink: XCRT) CEO Michael O’Shea discussed the company's innovative use of artificial intelligence (AI) to enhance healthcare access in remote areas of Tanzania. The AI-driven software, initially designed for self-driving cars, allows patients to connect with healthcare professionals via mobile devices, improving treatment efficiency. Xcelerate aims to launch a beta site by Q2 2022 and anticipates generating revenue by year-end. Additionally, the company plans to file several patents related to its technology, aiming for an uplisting to OTCQB.
Xcelerate, Inc. (OTC Pink: XCRT) has acquired a 51% stake in AfiyaSasa Africa, LLC to improve healthcare access in Africa. CEO Michael O’Shea announced that Dr. Dilan Elegalla has moved to Tanzania to lead a pilot program, with Sriyanjit Perera as CEO of ASA. The initiative aims to utilize patented telemedicine technology to connect patients with physicians via mobile devices. With 650 million mobile users in Africa, ASA expects to launch a fully operational beta site by the end of Q2 2022 and become revenue-producing before year-end.